Document Type : Original Article
Authors
- Mehran Sadeghi 1
- Mohammad Kermani-Alghoraishi 1
- Alireza Khosravi 2
- Atefeh Amerizadeh 3
- Masoumeh Sadeghi, MD 4
1 Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
2 Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
3 Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
4 Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
INTRODUCTION: Ticagrelor monotherapy after short-term (1-3 months) dual antiplatelet therapy (DAPT) with aspirin and ticagrelor can reduce bleeding without increasing ischemic events after percutaneous coronary intervention (PCI). However, its effect in diabetic and non-diabetic individuals has not been evaluated as a meta-analysis so far.
METHOD: This systematic review and meta-analysis were conducted covering PubMed, ISI Web of Science, and Scopus without date restrictions for English published clinical trials. The authors searched the mentioned databases, wherein the screening led to 151 studies, of which 40 were assessed for eligibility, and finally, three studies were included. These trials compared ticagrelor monotherapy after a short duration of aspirin plus ticagrelor with conventional 12 months DAPT.
RESULTS: The results showed that the risk of major bleeding (based on Bleeding Academic Research Consortium (BARC) type 3 or 5) for ticagrelor monotherapy subjects was lower in both diabetics and non-diabetics. It was especially significant in non-diabetic patients (HR 95%CI: 0.79(0.64, 0.98); p=0.029). In cardiovascular events assessment, the pooled estimate on cardiac deaths was significantly lower in diabetic subjects treated by ticagrelor monotherapy (HR 95%CI: 0.71(0.51, 1); p=0.05), while this reduction was not significant for non-diabetics (p=0.843) in comparison to patients treated by 12 months DAPT. However, there was no significant decrease or rise in myocardial infarction (MI) and ischemic stroke in patients treated by short-term DAPT strategy.
CONCLUSION: In conclusion, discontinuing aspirin after short-duration DAPT could minimize the incidence of cardiac death and BARC type 3 or 5 bleeding in diabetic and non-diabetic patients who underwent PCI, with no increase in MI and ischemic stroke.
Keywords
2. Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol 2015; 12(1): 30-47. https://doi.org/10.1038/nrcardio.2014.156
3. Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ. ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison. J Am Coll Cardiol 2018; 72(23 Pt A): 2915-31.https://doi.org/10.1016/j.jacc.2018.09.057
4. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49(14): 1505-16. https://doi.org/10.1016/j.jacc.2006.11.044
5. Armstrong PC, Leadbeater PD, Chan MV, Kirkby NS, Jakubowski JA, Mitchell JA, et al. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost 2011; 9(3): 552-61. https://doi.org/10.1111/j.1538-7836.2010.04160.x
6. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62(24): 2261-73.https://doi.org/10.1016/j.jacc.2013.07.101
7. Capodanno D, Huber K, Mehran R, Lip GYH, Faxon DP, Granger CB, et al. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review. J Am Coll Cardiol 2019; 74(1): 83-99. https://doi.org/10.1016/j.jacc.2019.05.016
8. Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, et al. International Expert Consensus on Switching Platelet P2Y(12) Receptor-Inhibiting Therapies. Circulation 2017; 136(20): 1955-75. https://doi.org/10.1161/CIRCULATIONAHA.117.031164
9. Saito Y, Kobayashi Y. Update on Antithrombotic Therapy after Percutaneous Coronary Intervention. Intern Med 2020; 59(3): 311-21. https://doi.org/10.2169/internalmedicine.3685-19
10. Rollini F, Franchi F, Cho JR, DeGroat C, Bhatti M, Muniz-Lozano A, et al. A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. Eur Heart J 2016; 37(35): 2722-30. https://doi.org/10.1093/eurheartj/ehv744
11. O’Donoghue ML, Murphy SA, Sabatine MS. The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y(12) Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Circulation 2020; 142(6): 538-45. https://doi.org/10.1161/CIRCULATIONAHA.120.046251
12. Kedhi E, Généreux P, Palmerini T, McAndrew TC, Parise H, Mehran R, et al. Impact of coronary lesion complexity on drug-eluting stent outcomes in patients with and without diabetes mellitus: analysis from 18 pooled randomized trials. J Am Coll Cardiol 2014; 63(20): 2111-8. https://doi.org/10.1016/j.jacc.2014.01.064
13. James S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny F, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2010; 31(24): 3006-16.https://doi.org/10.1093/eurheartj/ehq325
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327(7414): 557-60. https://doi.org/10.1136/bmj.327.7414.557
15. DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials 2015; 45(Pt A): 139-45. https://doi.org/10.1016/j.cct.2015.09.002
16. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109): 629-34. https://doi.org/10.1136/bmj.315.7109.629
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7(3): 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
18. Angiolillo DJ, Baber U, Sartori S, Briguori C, Dangas G, Cohen DJ, et al. Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol 2020; 75(19): 2403-13. https://doi.org/10.1016/j.jacc.2020.03.008
19. Yun KH, Cho JY, Lee SY, Rhee SJ, Kim BK, Hong MK, et al. Ischemic and Bleeding Events of Ticagrelor Monotherapy in Korean Patients With and Without Diabetes Mellitus: Insights From the TICO Trial. Front Pharmacol 2021; 11(2292). https://doi.org/10.3389/fphar.2020.620906
20. Chichareon P, Modolo R, Kogame N, Takahashi K, Chang CC, Tomaniak M, et al. Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study. Atherosclerosis 2020; 295: 45-53. https://doi.org/10.1016/j.atherosclerosis.2020.01.002
21. Schramm TK, Gislason GH, Køber L, Rasmussen S, Rasmussen JN, Abildstrøm SZ, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008; 117(15): 1945-54. https://doi.org/10.1161/CIRCULATIONAHA.107.720847
22. Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 2011; 123(7): 798-813. https://doi.org/10.1161/CIRCULATIONAHA.109.913376
23. Rios JRR, Franchi F, Rollini F, Angiolillo DJ. Diabetes and antiplatelet therapy: from bench to bedside. Cardiovasc Diagn Ther 2018; 8(5): 594. https://doi.org/10.21037/cdt.2018.05.09
24. Beckman JA, Paneni F, Cosentino F, Creager MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J 2013; 34(31): 2444-52. https://doi.org/10.1093/eurheartj/eht142
25. Creager MA, Lüscher TF, of pwta, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003; 108(12): 1527-32. https://doi.org/10.1161/01.CIR.0000091257.27563.32
26. Stratmann B, Tschoepe D. Pathobiology and cell interactions of platelets in diabetes. Diabetes Vasc Dis Res 2005; 2(1): 16-23. https://doi.org/10.3132/dvdr.2005.001
27. Geisler T, Anders N, Paterok M, Langer H, Stellos K, Lindemann S, et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007; 30(2): 372-4.https://doi.org/10.2337/dc06-1625
28. Serebruany V, Pokov I, Kuliczkowski W, Chesebro J, Badimon J. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost 2008; 100(07): 76-82. https://doi.org/10.1160/TH08-03-0136
29. Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care 2009; 32(4): 531-40.https://doi.org/10.2337/dc08-2064
30. Ferroni P, Basili S, Falco A, Davì G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost. 2004; 2(8): 1282-91. https://doi.org/10.1111/j.1538-7836.2004.00836.x
31. Koskinas KC, Siontis GCM, Piccolo R, Franzone A, Haynes A, Rat-Wirtzler J, et al. Impact of Diabetic Status on Outcomes After Revascularization With Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity. Circ Cardiovasc Interv 2016; 9(2): e003255. https://doi.org/10.1161/CIRCINTERVENTIONS.115.003255
32. Konigstein M, Ben-Yehuda O, Smits PC, Love MP, Banai S, Perlman GY, et al. Outcomes Among Diabetic Patients Undergoing Percutaneous Coronary Intervention with Contemporary Drug-Eluting Stents: Analysis From the BIONICS Randomized Trial. JACC Cardiovasc Interv 2018; 11(24): 2467-76.https://doi.org/10.1016/j.jcin.2018.09.033
33. Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med 2019; 381(21): 2032-42. https://doi.org/10.1056/NEJMoa1908419
34. Kim B-K, Hong S-J, Cho Y-H, Yun KH, Kim YH, Suh Y, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA 2020; 323(23): 2407-16. https://doi.org/10.1001/jama.2020.7580
35. Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 2018; 392(10151): 940-9. https://doi.org/10.1016/S0140-6736(18)31858-0
36. Kim C, Hong S-J, Shin D-H, Kim B-K, Ahn C-M, Kim J-S, et al. Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design. Am Heart J 2019; 212: 45-52. https://doi.org/10.1016/j.ahj.2019.02.015
)